TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02472041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reanimator group
Description: Resuscitator of Muller Group (intermittent positive pressure): Patients allocated to this group received intermittent positive pressure breathing (resuscitator Muller, Engemed, Brazil), adjusting the positive pressure around 1.5 kgf / cm2, which corresponds to 15 20 cm / H2O, positive pressure was applied through a face mask (Respironics®).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control
Description: Control Group: In position Fowler 45, patients assigned to this group was administered as treatment lung expansion exercises using the incentive inspiratory flow (Respiron, NCS, Mexico) and concomitantly blocking contralateral to the drain maneuvers were performed, compression / decompression associated with the incentive spirometry (Respiron) consisting of 4 sets of 10 active patient breaths with an interval of two minutes between sets. Since the load of the respiratory stimulator will be zero throughout treatment. Guidelines to the active, progressive and early mobilization.
Study: NCT01053299

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: open, prospective cohort-study
Description: Specific measurements from the X-ray to assess the hip status 5-12 years from the born.
Study: NCT04701385

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography (OCT)
Description: Optical Coherence Tomography (OCT) can undertake detailed characterisation of plaque morphology in patients with myocardial infarction at the time of percutaneous treatment. This allows plaque rupture, erosion and other mechanisms of myocardial infarction to be differentiated
Study: NCT02689284

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Margetuximab 10 mg/kg
Description: Margetuximab treatment is administered intravenously (IV) once every 21-day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Margetuximab 15 mg
Description: Margetuximab treatment is administered IV once every 21-day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab treatment is administered IV once every 21-day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab treatment is administered IV once every 21-day cycle
Study: NCT01621230

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epidural Bupivacaine plus fentanyl
Description: The subjects will receive 0.125% bupivacaine with fentanyl 2 mcg/mL at a rate of 10 mL/hr.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural fentanyl
Description: The subjects will receive epidural fentanyl 10 mcg/mL with the rate of 10mL/hr.
Study: NCT03260634

Intervention type: DRUG
Intervention: Voriconazole
Study: NCT01154244

Intervention type: OTHER
Intervention: HOMA-IR
Description: Blood sampling for HOMA-IR and HbA1C, fasting glucose, C-peptide, Lipid profile
Study: NCT03079206

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Food challenge
Description: food challenge with hazelnut

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: skin testing
Description: Skin testing with hazelnut extract

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: blood sampling to perform basophile activation tests
Study: NCT02057796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF®, Determine TB LAM, Chest X-ray
Description: The following point-of-care TB tests will be systematically performed:~Xpert MTB/RIF® on sputum (in all patients able to provide sputum; no sputum induction will be requested in others), Urine LAM (all patients). Depending on clinical presentation, Xpert MTB/RIF® will also be performed on any relevant extra-pulmonary specimen.~TB treatment will depend on the result of the tests:~Criteria met for confirmed or probable TB : TB treatment will be initiated immediately (Visit 1) followed by ART initiation 2 weeks later (Visit 2); No evidence of confirmed or probable TB: ART will be started immediately (Visit 1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART (Atripla, Truvada, Efavirenz, Combivir)
Description: * ART (TDF-3TC/FTC or AZT-3TC + efavirenz) will be started immediately after randomization in patients not put on TB treatment, and 2 weeks after initiation of TB treatment in others.~* ART will be initiated 2 weeks after the onset of TB treatment (V2) for Arm 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART (Atripla, Truvada, Efavirenz, Combivir)
Description: * ART (TDF-3TC/FTC or AZT-3TC + efavirenz) will be started immediately after randomization in patients not put on TB treatment, and 2 weeks after initiation of TB treatment in others.~* ART will be initiated 2 weeks after the onset of TB treatment (V2) for Arm 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin, isoniazid, pyrazinamide, ethambutol
Description: Arm 1: Only patients who meet standardized criteria for TB at inclusion or during follow-up will receive a standard TB treatment (2ERHZ/4RH); Arm 2: • All patients will start a 6-month standard TB treatment (2ERHZ/4RH) at randomization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin, isoniazid, pyrazinamide, ethambutol
Description: Arm 1: Only patients who meet standardized criteria for TB at inclusion or during follow-up will receive a standard TB treatment (2ERHZ/4RH); Arm 2: • All patients will start a 6-month standard TB treatment (2ERHZ/4RH) at randomization
Study: NCT02066311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Study: NCT02774447

Intervention type: PROCEDURE
Intervention: ileostoma closure
Description: The operation procedure is standardized as described above (see group description).The patients will be observed for 23 hours, and if there are no contraindications according to described criteria the patient can be discharged form the hospital, however all patients will have follow-up telephone contact on a daily basis with a nurse for the first week. Patients will meet the surgeon 3 days after discharge and after 4 weeks.
Study: NCT04886648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Study: NCT04427150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory Training
Description: A series of psychoacoustic training exercises through Posit Science - BrainHQ (mobile app or web-browser version). Each training is approximately 2 minutes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-auditory training
Description: A series of non-psychoacoustic training exercises through Posit Science - BrainHQ (mobile app or web-browser version). Each training is approximately 2 minutes
Study: NCT04530903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: 75 µg (0.5mL) per injection site

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levobupivacaine
Description: 0.25% (10 ml) per injection site

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: 0.25% (10 ml) per injection site

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: Nacl 0.9% (0.5ml) per injection site
Study: NCT04498208

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Prehabilitation
Description: First, an evaluation of patient's aerobic capacity, functional mobility, functional strength, ambulation, fall risk, and overall mobility will be done by a trained member of the research team. Based on their functional level and preexisting conditions, therapeutic exercises will be recommended to optimize their strength, endurance, flexibility, and functional mobility in preparation for surgery. Decisions about the interventions are based on the assessment, individual patient characteristics, environmental factors, surgical type, and monitoring of the client's response and progress. Weekly sessions are 30-45 minutes long to monitor the client's response and progress their program. Based on their response to exercise (evaluated also by 2 apps: Timed Walk App and Smart Metronome \& Tuner App), re-evaluation via the assessments described above, change their plan of care (alter frequency, resistance, exercises) or discontinuation of treatment could be decided.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Reduction Prehabilitation
Description: Participants will have the opportunity to learn techniques for mindfulness that have been established to reduce stress and assist with pain management with a member of the research team. Patients will be offered to listen to audio recording of relaxation sessions. Each session contains a relaxation technique that the patient practices while listening to the recording. Then the technique is used the next as a baseline to introduce a new technique more advanced. For some patients who struggle with the techniques the program will be adapted. Patients will choose 2 or 3 techniques and work on them.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Prehabilitation
Description: Cognitive prehabilitation will consist on the daily use of Lumosity training program, an already existing free app built to increase memory skills. The program proposed by Lumosity is tailored to each patient. The use of Lumosity will be monitored at each in-person session. Patients will be expected to complete at least three 5-minute sessions of Lumosity training per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Prehabilitation
Description: Nutrition prehabilitation will involve transitioning the patient to the Mediterranean diet with targets regarding hydration and the proportion of fruits, vegetables, whole grains, and healthy fats the patient will consume in a given day. This nutritional program is flexible, and it allows for specific physician and nutritionist-recommended dietary needs to be incorporated. The patient is also given tools to encourage success in healthier eating, including recipes, sample menus, healthy restaurant options, meal kit options, and local CSA box options
Study: NCT01683279

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CD19 CAR+ EGFTt + T cells
Description: Autologous T cell modified to express a CD19 specific CAR and a truncated EGFRt tag
Study: NCT01686009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-nasal ketamine
Study: NCT01372150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desvenlafaxine succinate sustained release
Description: Subjects randomized to DVS SR group receive 25, 35 or 50 mg/day based on subject weight at the Baseline visit. DVS SR provided as oral tablets.

Intervention type: DRUG
Group type: OTHER
Intervention: fluoxetine
Description: Subjects randomized to the fluoxetine group receive 20 mg/day. Fluoxetine provided as oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subjects randomized to the placebo group receive corresponding placebo tablets and/capsules
Study: NCT01617590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leflunomide
Description: Leflunomide 10-20 mg, orally, once daily for up to 48 weeks. Twelve weeks after the initial Leflunomide induction, patients were randomized into two groups (LEF+CTX:LEF+MTX=2:1) if the DAS 28 were higher than 2.6, or continuing leflunomide use without dosing change. Then, the disease activity was assessed using DAS 28 every 12 weeks. The regimen should remain unchanged if the DAS 28 reached to less than 2.6, otherwise, a third (24 weeks) or fourth (36 weeks) DMARs should be added.~Intravenous CTX was administrated once 200-400mg per 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: MTX 7.5-15 mg, orally, once weekly for up to 48 weeks. Twelve weeks after the initial MTX induction, patients were randomized into two groups (MTX+CTX:LEF+MTX=2:1) if the DAS 28 were higher than 2.6, or continuing MTX use without dosing change. Then, the disease activity was assessed using DAS 28 every 12 weeks. The regimen should remain unchanged if the DAS 28 reached to less than 2.6, otherwise, a third (24 weeks) or fourth (36 weeks) DMARs should be added.~Intravenous CTX was administrated once
Study: NCT01054144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: * Starting Dose: 25 mg by mouth (PO) days 1-21 of a 28 days cycle;~* Dose Level -1: 15 mg PO days 1-21 of a 28 days cycle;~* Dose Level -2: 10 mg PO days 1-21 of a 28 days cycle;~* Dose Level -3: 5 mg PO days 1-21 of a 28 days cycle;~* Dose Level -4: Discontinue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: * Starting Dose: 100 mg PO days 1-5 every 28 days;~* Dose level -1: 50 mg PO days 1-5 of a 28 day cycle;~* Dose level -2: 25 mg PO days 1-5 of a 28 day cycle;~* Dose level -3: Discontinue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: * Starting Dose: 40 mg daily on days 1 - 4 every 28 days;~* Dose level -1: 20 mg daily on days 1 - 4 every 28 days;~* Dose level -1a: 40 mg daily on days 1, 2, and 3 followed by 20 mg on day 4 followed by 12 mg on day 5 followed by 8 mg on day 6;~* Dose level -2: 10 mg daily on days 1 - 4 every 28 days;~* Dose level -3: Discontinue
Study: NCT01684072

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: vaccine without gelatin
Description: use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaccine without gelatin
Description: use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: vaccine with gelatin
Description: use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaccine with gelatin
Description: use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
Study: NCT04159142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel + Carboplatin
Description: nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel + Capecitabine
Description: Nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and capecitabine given IV at 1000 mg/m\^2 bid, d1-14 every 21 days x 6 cycles；
Study: NCT04823572

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: A-PRF/OFD
Description: Comparing healing effect of an autologous and open flap debridement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: A-PRF/OFD
Description: Comparing healing effect of an autologous and open flap debridement
Study: NCT01213875

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home based education
Description: There will provided education about what is heart failure, its causes, how to recognize signs and symptoms, monitoring of weight and blood pressure, the importance of compliance to treatment. Patients will be instructed about the medications; a guide to rest and exercise, sexual activity, vaccines, travel and diet will be provided. The involvement of the family will be encouraged; the contact with the team should be done when: patient observes an increase of 1 or 2 kg of weight in 2-3 days, worsening of dyspnea on effort, edema in legs / abdomen, worsening of cough, persistent vomiting, syncope,sputum with blood, fever, persistent tachycardia. In phone calls made between home visits, the compliance to treatment will be evaluated and reinforced.
Study: NCT02475070

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vildagliptin
Description: Vildagliptin added at 50 mg twice daily for two weeks followed by four weeks washout and then dapagliflozin 10mg once daily for two weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vildagliptin
Description: Vildagliptin added at 50 mg twice daily for two weeks followed by four weeks washout and then dapagliflozin 10mg once daily for two weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Dapagliflozin added at 10 mg once daily for two weeks followed by four weeks washout and then vildagliptin 50 mg twice daily for two weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Dapagliflozin added at 10 mg once daily for two weeks followed by four weeks washout and then vildagliptin 50 mg twice daily for two weeks
Study: NCT02330887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Antenatal Care
Description: The group antenatal care intervention will match pregnant women by gestational age in the intervention village clusters and assign them to peer group sessions facilitated by local healthcare clinic staff.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individual Antenatal Care
Description: Pregnant women in control village clusters will have individual antenatal care sessions with their healthcare provider.
Study: NCT00859599

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monochromatic phototherapy, Biolight®
Description: Monochromatic phototherapy (Biolight®) will be given locally, additional to standard care, three times weekly during the first four weeks and twice weekly the following sixteen weeks or until the ulcer is completely healed, according to a pre-determined treatment plan.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Monochromatic phototherapy, Biolight®
Description: Monochromatic phototherapy (Biolight®) will be given locally, additional to standard care, three times weekly during the first four weeks and twice weekly the following sixteen weeks or until the ulcer is completely healed, according to a pre-determined treatment plan.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monochromatic phototherapy
Description: Monochromatic phototherapy (Biolight®) will be given locally, additional to standard care, three times weekly during the first four weeks and twice weekly the following sixteen weeks or until the ulcer is completely healed, according to a pre-determined treatment plan.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Monochromatic phototherapy
Description: Monochromatic phototherapy (Biolight®) will be given locally, additional to standard care, three times weekly during the first four weeks and twice weekly the following sixteen weeks or until the ulcer is completely healed, according to a pre-determined treatment plan.
Study: NCT03000088

Intervention type: DEVICE
Intervention: intubate with 60° angled stylet

Intervention type: DEVICE
Intervention: intubate with 60° angled stylet
Study: NCT04227886

Intervention type: RADIATION
Intervention: Radiation
Description: Neoadjuvant radiotherapy consisted of 50 Gy in 25 fractions using intensity-modulated radiotherapy to the primary tumor and to mesorectal, presacral, and internal iliac lymph nodes.

Intervention type: RADIATION
Intervention: Radiation
Description: Neoadjuvant radiotherapy consisted of 50 Gy in 25 fractions using intensity-modulated radiotherapy to the primary tumor and to mesorectal, presacral, and internal iliac lymph nodes.

Intervention type: RADIATION
Intervention: Radiation
Description: Neoadjuvant radiotherapy consisted of 50 Gy in 25 fractions using intensity-modulated radiotherapy to the primary tumor and to mesorectal, presacral, and internal iliac lymph nodes.

Intervention type: RADIATION
Intervention: Radiation
Description: Neoadjuvant radiotherapy consisted of 50 Gy in 25 fractions using intensity-modulated radiotherapy to the primary tumor and to mesorectal, presacral, and internal iliac lymph nodes.

Intervention type: DRUG
Intervention: Capecitabine-Irinotecan Combination
Description: The concurrent chemotherapy consists of capecitabine 625 mg/m2 twice daily 5 days per week and combined with weekly irinotecan. The irinotecan dose was used based on UGT1A1 genotype of 80mg/m2 for UGT1A1\*1\*1 or 65mg/m2 for UGT1A1\*1\*28 weekly, followed by a cycle of XELIRI.

Intervention type: DRUG
Intervention: Capecitabine-Irinotecan Combination
Description: The concurrent chemotherapy consists of capecitabine 625 mg/m2 twice daily 5 days per week and combined with weekly irinotecan. The irinotecan dose was used based on UGT1A1 genotype of 80mg/m2 for UGT1A1\*1\*1 or 65mg/m2 for UGT1A1\*1\*28 weekly, followed by a cycle of XELIRI.

Intervention type: DRUG
Intervention: Capecitabine-Irinotecan Combination
Description: The concurrent chemotherapy consists of capecitabine 625 mg/m2 twice daily 5 days per week and combined with weekly irinotecan. The irinotecan dose was used based on UGT1A1 genotype of 80mg/m2 for UGT1A1\*1\*1 or 65mg/m2 for UGT1A1\*1\*28 weekly, followed by a cycle of XELIRI.

Intervention type: DRUG
Intervention: Capecitabine-Irinotecan Combination
Description: The concurrent chemotherapy consists of capecitabine 625 mg/m2 twice daily 5 days per week and combined with weekly irinotecan. The irinotecan dose was used based on UGT1A1 genotype of 80mg/m2 for UGT1A1\*1\*1 or 65mg/m2 for UGT1A1\*1\*28 weekly, followed by a cycle of XELIRI.